Moderate doses of interferon alpha 2b with concurrent hydroxyurea in patients of chronic myeloid leukemia benefits early, late chronic phase and acelerated phase: Five year follow up
Ranga Rao Rangaraju*, Subramanya Y. Sarma, Lakhtakia Ritu, Nandi Jayasree
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Moderate doses of interferon alpha 2b with concurrent hydroxyurea in patients of chronic myeloid leukemia benefits early, late chronic phase and acelerated phase: Five year follow up'. Together they form a unique fingerprint.